MEI Pharma Inc
NASDAQ:MEIP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
MEI Pharma Inc
NASDAQ:MEIP
|
US |
Balance Sheet
Balance Sheet Decomposition
MEI Pharma Inc
MEI Pharma Inc
Balance Sheet
MEI Pharma Inc
| Jun-2015 | Jun-2016 | Jun-2017 | Jun-2018 | Jun-2019 | Jun-2020 | Jun-2021 | Jun-2022 | Jun-2023 | Jun-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
19
|
11
|
9
|
13
|
10
|
12
|
9
|
16
|
17
|
4
|
|
| Cash Equivalents |
19
|
11
|
9
|
13
|
10
|
12
|
9
|
16
|
17
|
4
|
|
| Short-Term Investments |
45
|
35
|
45
|
89
|
65
|
170
|
145
|
138
|
84
|
35
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
6
|
23
|
8
|
10
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
1
|
3
|
8
|
10
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
5
|
20
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
1
|
1
|
2
|
2
|
2
|
3
|
4
|
4
|
7
|
2
|
|
| Total Current Assets |
64
|
47
|
55
|
104
|
82
|
209
|
165
|
167
|
108
|
41
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
1
|
9
|
11
|
13
|
1
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
1
|
9
|
11
|
13
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
65
N/A
|
47
-27%
|
56
+18%
|
105
+88%
|
83
-21%
|
210
+154%
|
174
-17%
|
178
+2%
|
121
-32%
|
41
-66%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1
|
1
|
1
|
4
|
5
|
2
|
6
|
8
|
6
|
3
|
|
| Accrued Liabilities |
4
|
4
|
3
|
4
|
5
|
6
|
9
|
12
|
14
|
5
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
1
|
1
|
5
|
5
|
5
|
5
|
0
|
0
|
|
| Total Current Liabilities |
5
|
6
|
5
|
8
|
14
|
14
|
20
|
24
|
20
|
8
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
46
|
20
|
119
|
104
|
101
|
76
|
0
|
|
| Total Liabilities |
5
N/A
|
6
+10%
|
5
-11%
|
54
+1 006%
|
35
-36%
|
133
+282%
|
125
-6%
|
125
+1%
|
96
-23%
|
8
-91%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
156
|
177
|
174
|
214
|
231
|
278
|
320
|
374
|
406
|
388
|
|
| Additional Paid In Capital |
216
|
219
|
225
|
265
|
279
|
356
|
369
|
427
|
431
|
421
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
60
N/A
|
42
-30%
|
51
+22%
|
51
-1%
|
48
-5%
|
77
+61%
|
50
-36%
|
52
+6%
|
25
-53%
|
33
+34%
|
|
| Total Liabilities & Equity |
65
N/A
|
47
-27%
|
56
+18%
|
105
+88%
|
83
-21%
|
210
+154%
|
174
-17%
|
178
+2%
|
121
-32%
|
41
-66%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
2
|
2
|
2
|
4
|
4
|
6
|
6
|
7
|
7
|
7
|
|